Back to Search
Start Over
Nipocalimab May Reduce NMJ Damage Without Suppressing Complement Function
- Source :
- Clinical Advisor. November 3, 2023
- Publication Year :
- 2023
-
Abstract
- PHOENIX, Arizona—Nipocalimab might lower the concentration of anti-acetylcholine receptor antibodies, or anti-AChR antibodies, in people with https://www.rarediseaseadvisor.com/junction-hub-pages/myasthenia-gravis/, reducing neuromuscular junction (NMJ) damage without completely suppressing the complement pathway function, according [...]
- Subjects :
- Johnson & Johnson
Pharmaceutical industry -- Research
Health
Subjects
Details
- Language :
- English
- ISSN :
- 15247317
- Database :
- Gale General OneFile
- Journal :
- Clinical Advisor
- Publication Type :
- Periodical
- Accession number :
- edsgcl.771248688